Literature DB >> 6471901

A plasma clot culture system for growing and antiproliferative drug sensitivity testing of myeloma stem cells.

H Ludwig, E Fritz, D Peest.   

Abstract

An easy-to-perform clonogenic culture system for myeloma stem cells is presented which approaches the patient's in vivo situation more closely and therefore seems particularly well-suited for antiproliferative drug sensitivity assays. Bone marrow cells are propagated in clotted autologous or allogenic plasma that is enriched with 2-mercaptoethanol, insulin, and synthetic nucleotides and co-factors for nuclear synthesis, no feeder layer or conditioned medium is necessary. Clusters and colonies consisting of between 8 and 60 cells readily formed within 6-8 days after cloning yielding a plating efficiency between 0.12 and 2.16%. A linear relationship between the number of cells plated and colony formation was found from 10(5) through 2 X 10(6) cells plated. The successful growth rate for 65 tests from 53 patients amounted to 90.8%. Morphological and histochemical examination of the clusters revealed lymphoid cells at various stages of maturation ranging from lymphocytic and lymphoblastoid to lymphoplasmacytic and plasma cells. Tumor origin of the clones was demonstrated by immunofluorescence studies in which Ig-positive cells stained only for the heavy and light chain isotypes identical to those of the patient's serum paraprotein. Anti-idiotypic antisera confirmed the patient's specific malignant phenotype of the colonies formed. The technique of the assay is described in detail.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6471901     DOI: 10.1016/0145-2126(84)90018-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  In situ immunocytochemical staining of cell colonies growing in plasma clot.

Authors:  A Bontadini; M Gobbi; A Dinota; P L Tazzari; M T Rivano; S Pileri
Journal:  Histochemistry       Date:  1988

2.  Cytostatic drug sensitivity test for human multiple myeloma, measuring monoclonal immunoglobulin produced by bone marrow cells in vitro.

Authors:  D Peest; B Bartels; I Dallmann; I Schedel; H Deicher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.